Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adma Biologics 465 STATE ROUTE 17 RAMSEY NJ 07446 USA

www.admabiologics.com Employees: 624 P: 201-478-5552 F: 201-478-5553

Description:

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 4,113,186
Enterprise Value, $K 4,192,426
Shares Outstanding, K 236,390
Annual Sales, $ 258,220 K
Annual Net Income, $ -28,240 K
Last Quarter Sales, $ 119,840 K
Last Quarter Net Income, $ 35,910 K
EBIT, $ 115,440 K
EBITDA, $ 126,220 K
60-Month Beta 0.70
% of Insider Shareholders 3.70%
% of Institutional Shareholders 75.68%
Float, K 227,644
% Float 96.30%
Short Volume Ratio 0.60

Growth:

1-Year Return 325.43%
3-Year Return 1,270.08%
5-Year Return 340.51%
5-Year Revenue Growth 1,419.84%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.15 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm 0.40
EPS Growth vs. Prev Qtr 15.38%
EPS Growth vs. Prev Year 1,400.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ADMA Ratios

Ratio
Price/Earnings ttm 44.75
Price/Earnings forward 34.65
Price/Earnings to Growth N/A
Return-on-Equity % 53.20%
Return-on-Assets % 26.07%
Profit Margin % -10.94%
Debt/Equity 0.44
Price/Sales 16.39
Price/Cash Flow 352.24
Price/Book 18.25
Book Value/Share 0.98
Interest Coverage -0.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar